SCHEMBL1030675

SCHEMBL1030675

Clc1ccc2cccc(Br)c2n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.64
SLC40A1 Q9NP59 2/20 0.42
AR P10275 1/20 0.40
ENPP3 O14638 1/20 0.39
ENPP1 P22413 1/20 0.39
MCHR1 Q99705 1/20 0.36
HSP90AA1 P07900 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
GRM2 Q14416 1/20 0.36
EGFR P00533 1/20 0.36
PIM1 P11309 2/20 0.35
PIM2 Q9P1W9 2/20 0.35
NOS1 P29475 1/20 0.35
PLAU P00749 1/20 0.35
NCF1 P14598 1/20 0.35
LMNA P02545 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15228915 0.78 BACE1 (1.00) BACE1MCHR1PLAUNCF1
SCHEMBL339928 0.77 BACE1 (0.63) BACE1ARENPP3ENPP1HSP90AA1
SCHEMBL30657716 0.77 BACE1 (0.63) BACE1ARENPP3ENPP1HSP90AA1
SCHEMBL845037 0.77 SLC40A1 (0.45) BACE1SLC40A1ARMCHR1HSP90AA1
SCHEMBL29683992 0.77 SLC40A1 (0.45) BACE1SLC40A1ARMCHR1HSP90AA1
SCHEMBL31387642 0.76 BACE1 (0.36) BACE1SLC40A1EGFR
SCHEMBL21631384 0.76 BACE1 (0.36) BACE1SLC40A1EGFR
SCHEMBL29533844 0.75 CCR1 (0.43) SLC40A1MCHR1HSP90AA1RAB9APIM1
SCHEMBL557084 0.75 CCR1 (0.43) SLC40A1MCHR1HSP90AA1RAB9APIM1
SCHEMBL1967396 0.74 SLC40A1 (0.42) BACE1SLC40A1ARMCHR1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119285543-B Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2026-05-15 CN claimed
CN-119285543-A Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2025-01-10 CN claimed
CN-119285543-B Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2026-05-15 CN disclosed
US-12600719-B2 Salt inducible kinase inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2026-04-14 US disclosed
EP-4363415-B1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) 2025-12-10 EP disclosed
EP-4660192-A1 SALT INDUCIBLE KINASE INHIBITORS The General Hospital Corporation (US) 2025-12-10 EP disclosed
US-20250333371-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-10-30 US disclosed
EP-4554680-A1 INHIBITORS OF HPK1 AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2025-05-21 EP disclosed
EP-4532462-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-04-09 EP disclosed
CN-119384406-A Compounds of formula (I) 赛洛私人有限公司 2025-01-28 CN disclosed
CN-119285543-A Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2025-01-10 CN disclosed
EP-1235825-B1 NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS PFIZER PROD INC (US) 2006-01-25 EP disclosed
US-6821967-B2 AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-11-23 US disclosed
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-09-04 US disclosed
CN-1402721-A Novel benzimidazole derivatives as antiproliferative agents PFIZER PROD INC (US) 2003-03-12 CN disclosed
EP-1255736-A2 SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) Boehringer Ingelheim Pharma KG (DE) 2002-11-13 EP disclosed
EP-1235825-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS Pfizer Products Inc. (US) 2002-09-04 EP disclosed
WO-2001047898-A2 SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-07-05 WO disclosed
WO-2001040217-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS PFIZER PRODUCTS INC. (US) 2001-06-07 WO disclosed
US-5372813-A Measurement of serotonin uptake sites in a sample using a radio labeled substituted 6-nitroquipazine as a radioligand THE REGENTS, UNIVERSITY OF CALIFORNIA (US) 1994-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments MTTP, CETP, CPT1A BACE1 2331/4885SLC40A1 136/4885AR 3097/4885
US-12600719-B2 Salt inducible kinase inhibitors GRK6, SGK1, CSNK1A1 BACE1 4597/4885SLC40A1 4046/4885AR 1800/4885
US-20250333371-A1 COMPOUNDS SDHA, PYGB, SLC18A2 BACE1 554/4885SLC40A1 1265/4885AR 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.